Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

However, declining RSV vaccination rates in the US impacted total market volume. Prevnar 20 retained an 87% market share in the US, with pediatric sales holding two-thirds of revenues. Pfizer’s ...

Investigators randomly assigned participants in the United States and Japan in a 1:1 ratio to receive one dose of Pfizer’s bivalent (two-strain) RSV Prefusion F (RSVpreF) vaccine (Abrysvo ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

These findings have been implemented by GSK and Pfizer to utilize the pre-F RSV protein as their immunogen for vaccine research. The availability of high purity, conformationally verified proteins ...

The CDC encourages doctors to vaccinate babies and adults over 60 years old, with two RSV vaccines for seniors, GSK’s Arexvy (88% effective) and Pfizer’s Abrysvo(85% effective), currently ...